— Why it moved
Why VERU Stock Surged Today — June 4, 2026
Novo Nordisk agreed to hand Veru free Wegovy for a muscle-preservation trial, and a nine-day short cover queue turned a supply agreement into a 58% spike.
## What moved it Novo Nordisk will supply Wegovy at no cost for Veru's Phase 2b PLATEAU trial, which tests enobosarm against the muscle loss that comes with GLP-1 drugs. Not a buyout, not revenue — a clinical supply deal. The market treated it as validation of the obesity angle and paid up anyway.
## The mechanics A 13.7M float and a genuinely crowded short book at nine days to cover. The stock more than tripled off its morning low before lunch, and 92.9M shares traded — the float turned over almost seven times.
## Numbers - Cap: ~$36M / float: 13.7M - Day volume: 92.9M (~7x the float) - Prev close: $2.25 — no gap, this all happened mid-session - 52w range: $2.05–$7.40, and the peak nearly tagged the high
## Where it ended up The alert hit mid-run at 12:11 PM, $4.63. Fourteen minutes later it printed $7.33, up 58%. Then the air came out. It drifted lower all afternoon and closed at $4.23, 8.6% under the alert.
## Reality check - The entire afternoon was a fade; the close sat below the alert price. - Free trial drug isn't revenue. Veru still has to fund and run the study itself. - Real catalyst, but the spike on top of it was momentum. Post-mortem, not a pitch.